Advisory Committee on the Medical Uses of Isotopes: Meeting Notice, 20745-20746 [2021-08172]
Download as PDF
<![CDATA[
20745
khammond on DSKJM1Z7X2PROD with NOTICES
Federal Register / Vol. 86, No. 75 / Wednesday, April 21, 2021 / Notices
and ML in nuclear power industry
operations and management, as well as
potential pitfalls and challenges
associated with their application.
1. What is status of the commercial
nuclear power industry development or
use of AI/ML tools to improve aspects
of nuclear plant design, operations or
maintenance or decommissioning? What
tools are being used or developed?
When are the tools currently under
development expected to be put into
use?
2. What areas of commercial nuclear
reactor operation and management will
benefit the most, and the least, from the
implementation of AI/ML? Possible
examples include, but are not limited to,
inspection support, incident response,
power generation, cybersecurity,
predictive maintenance, safety/risk
assessment, system and component
performance monitoring, operational/
maintenance efficiency and shutdown
management.
3. What are the potential benefits to
commercial nuclear power operations of
incorporating AI/ML in terms of (a)
design or operational automation, (b)
preventive maintenance trending, and
(c) improved reactor operations staff
productivity?
4. What AI/ML methods are either
currently being used or will be in the
near future in commercial nuclear plant
management and operations? Example
of possible AI/ML methods include, but
are not limited to, artificial neural
networks, decision trees, random
forests, support vector machines,
clustering algorithms, dimensionality
reduction algorithms, data mining and
content analytics tools, gaussian
processes, Bayesian methods, natural
language processing, and image
digitization.
5. What are the advantages or
disadvantages of a high-level, top-down
strategic goal for developing and
implementing AI/ML across a wide
spectrum of general applications versus
an ad-hoc, case-by-case targeted
approach?
6. With respect to AI/ML, what phase
of technology adoption is the
commercial nuclear power industry
currently experiencing and why? The
current technology adoption model
characterizes phases into categories
such as: the innovator phase, the early
adopter phase, the early majority phase,
the late majority phase, and the laggard
phase.
7. What challenges are involved in
balancing the costs associated with the
development and application of AI/ML
tools, against plant operational and
engineering benefits when integrating
VerDate Sep<11>2014
18:12 Apr 20, 2021
Jkt 253001
AI/ML into operational decision-making
and workflow management?
8. What is the general level of AI/ML
expertise in the commercial nuclear
power industry (e.g. expert, well-versed/
skilled, or beginner)?
9. How will AI/ML effect the
commercial nuclear power industry in
terms of efficiency, costs, and
competitive positioning in comparison
to other power generation sources?
10. Does AI/ML have the potential to
improve the efficiency and/or
effectiveness of nuclear regulatory
oversight or otherwise affect regulatory
costs associated with safety oversight? If
so, in what ways?
11. AI/ML typically necessitates the
creation, transfer and evaluation of very
large amounts of data. What concerns, if
any, exist regarding data security in
relation to proprietary nuclear plant
operating experience and design
information that may be stored in
remote, offsite networks?
The teleconference meeting will
be held on Thursday, May 27, 2021,
1:00 p.m. to 5:00 p.m. Eastern Daylight
Time.
DATES:
Date
May 27, 2021 ...
Webinar information
Link: https://
usnrc.webex.com Event
number: 199 574 5068.
Dated: April 15, 2021.
For the Nuclear Regulatory Commission.
Mehdi Reisi Fard,
Chief, Performance and Reliability Branch,
Division of Risk Analysis, Office of Nuclear
Regulatory Research.
Public Participation: The meeting will
be held as a webinar using Cisco
WebEx. Any member of the public who
wishes to participate in any portion of
this meeting should register in advance
of the meeting by accessing the
provided link above. Upon successful
registration, a confirmation email will
be generated providing the telephone
bridge line and a link to join the
webinar on the day of the meeting.
Members of the public should also
monitor the NRC’s Public Meeting
Schedule at https://www.nrc.gov/pmns/
mtg for any meeting updates. If there are
any questions regarding the meeting,
persons should contact Ms. Jamerson
using the information below.
Contact Information: Kellee Jamerson,
email: Kellee.Jamerson@nrc.gov,
telephone: 301–415–7408.
[FR Doc. 2021–08177 Filed 4–20–21; 8:45 am]
Conduct of the Meeting
BILLING CODE 7590–01–P
The ACMUI Chair, Darlene F. Metter,
M.D., will preside over the meeting. Dr.
Metter will conduct the meeting in a
manner that will facilitate the orderly
conduct of business. The following
procedures apply to public participation
in the meeting:
1. Persons who wish to provide a
written statement should submit an
electronic copy to Ms. Jamerson at the
contact information listed above. All
written statements must be received by
May 24, 2021, three business days prior
to the meeting, and must pertain to the
topics on the agenda for the meeting.
2. Questions and comments from
members of the public will be permitted
during the meeting, at the discretion of
the ACMUI Chairman.
3. The draft transcript and meeting
summary will be available on ACMUI’s
website https://www.nrc.gov/readingrm/doc-collections/acmui/meetings/
2021.html on or about July 9, 2021.
4. Persons who require special
services, such as those for the hearing
impaired, should notify Ms. Jamerson of
their planned participation.
This meeting will be held in
accordance with the Atomic Energy Act
of 1954, as amended (primarily Section
161a); the Federal Advisory Committee
Act (5 U.S.C. App); and the
Commission’s regulations in 10 CFR
part 7.
NUCLEAR REGULATORY
COMMISSION
Advisory Committee on the Medical
Uses of Isotopes: Meeting Notice
U.S. Nuclear Regulatory
Commission.
ACTION: Notice of Meeting.
AGENCY:
The U.S. Nuclear Regulatory
Commission (NRC) will convene a
public teleconference meeting of the
Advisory Committee on the Medical
Uses of Isotopes (ACMUI) on May 27,
2021, to discuss the NRC staff’s
assessment of medical related events for
fiscal year 2020 and the ACMUI
Abnormal Occurrence Subcommittee’s
draft report on the proposed limited
revisions to abnormal occurrence
criteria for medical events. The meeting
agenda is subject to change. Meeting
information, including a copy of the
agenda and related documents, will be
available on the ACMUI’s Meetings and
Related Documents web page at https://
www.nrc.gov/reading-rm/doccollections/acmui/meetings/2021.html.
The agenda and related meeting
documents may also be obtained by
contacting Ms. Kellee Jamerson using
the information below.
SUMMARY:
PO 00000
Frm 00094
Fmt 4703
Sfmt 4703
E:\FR\FM\21APN1.SGM
21APN1
20746
Federal Register / Vol. 86, No. 75 / Wednesday, April 21, 2021 / Notices
Dated at Rockville, Maryland, this 15th day
of April 2021.
For the U.S. Nuclear Regulatory
Commission.
Russell E. Chazell,
Federal Advisory Committee Management
Officer.
[FR Doc. 2021–08172 Filed 4–20–21; 8:45 am]
BILLING CODE 7590–01–P
This notice identifies
Schedule A, B, and C appointing
authorities applicable to a single agency
that were established or revoked from
February 1, 2021 to February 28, 2021.
SUMMARY:
Julia
Alford, Senior Executive Resources
Services, Senior Executive Services and
Performance Management, Employee
Services, 202–606–2246.
FOR FURTHER INFORMATION CONTACT:
In
accordance with 5 CFR 213.103,
Schedule A, B, and C appointing
authorities available for use by all
agencies are codified in the Code of
Federal Regulations (CFR). Schedule A,
B, and C appointing authorities
applicable to a single agency are not
codified in the CFR, but the Office of
Personnel Management (OPM)
SUPPLEMENTARY INFORMATION:
OFFICE OF PERSONNEL
MANAGEMENT
Excepted Service
Office of Personnel
Management (OPM).
AGENCY:
ACTION:
Notice.
publishes a notice of agency-specific
authorities established or revoked each
month in the Federal Register at
www.gpo.gov/fdsys/. OPM also
publishes an annual notice of the
consolidated listing of all Schedule A,
B, and C appointing authorities, current
as of June 30, in the Federal Register.
Schedule A
No Schedule B Authorities to report
during February 2021.
Schedule B
No Schedule B Authorities to report
during February 2021.
Schedule C
The following Schedule C appointing
authorities were approved during
February 2021.
Authorization
No.
Agency name
Organization name
Position title
DEPARTMENT OF AGRICULTURE
Office of the Assistant Secretary
for Congressional Relations.
Agricultural Marketing Service .......
Legislative Analyst ..........................
DA210070
02/01/2021
Senior Advisor for Fair and Competitive Markets.
Senior Policy Advisor .....................
Policy Advisor .................................
Senior Advisor for Data and Technology.
Senior Policy Advisor .....................
Executive Assistant ........................
Senior Advisor (Upskilling and
Broadband).
Scheduler .......................................
DA210086
02/12/2021
DA210079
DA210089
DA210085
02/04/2021
02/23/2021
02/12/2021
DA210080
DC210081
DC210076
02/04/2021
02/05/2021
02/10/2021
DC210079
02/05/2021
Policy Advisor .................................
DC210083
02/05/2021
Deputy Director, Office of Policy
and Strategic Planning.
Senior Advisor ................................
Special Assistant ............................
Special Assistant (2) ......................
DC210086
02/10/2021
DC210087
DC210080
DD210191
DD210193
DD210204
02/25/2021
02/05/2021
02/12/2021
02/12/2021
02/18/2021
DD210173
DD210199
DD210175
DD210205
DD210194
DD210178
DD210186
DD210200
DD210170
DD210174
DD210189
DD210192
DD210177
02/02/2021
02/18/2021
02/02/2021
02/25/2021
02/12/2021
02/02/2021
02/12/2021
02/18/2021
02/02/2021
02/02/2021
02/12/2021
02/12/2021
02/02/2021
02/02/2021
02/02/2021
02/18/2021
02/16/2021
02/16/2021
02/16/2021
02/11/2021
02/11/2021
DEPARTMENT OF COMMERCE ...
Farm Service Agency .....................
Foreign Agricultural Service ...........
Office of the Assistant Secretary
for Administration.
Rural Utilities Service .....................
Immediate Office ............................
Office of Advance, Scheduling and
Protocol.
Office of Policy and Strategic Planning.
DEPARTMENT OF DEFENSE .......
Office of the Deputy Secretary .......
Office of the Assistant Secretary of
Defense (Legislative Affairs).
Office of the Assistant to the Secretary of Defense (Public Affairs).
Deputy Press Secretary .................
khammond on DSKJM1Z7X2PROD with NOTICES
Director of Digital Media .................
Research Assistant ........................
Speechwriter (2) .............................
Office of the Secretary of Defense
Deputy Director of Protocol ............
Special Assistant (3) ......................
Office of the Under Secretary of
Defense
(Acquisition
and
Sustainment).
Special Assistant (4) ......................
Office of the Under Secretary of
Defense (Personnel and Readiness).
Office of the Under Secretary of
Defense (Policy).
Special Assistant ............................
AIR
Office of the General Counsel .......
Attorney Advisor/Special Assistant
DD210172
DD210180
DD210202
DF210007
DEPARTMENT OF THE ARMY .....
Office of the Secretary ...................
Office of the Under Secretary ........
Office of the General Counsel .......
Office Assistant Secretary Army
(Civil Works).
Special Assistant ............................
Special Assistant ............................
Attorney Advisor .............................
Special Assistant ............................
DF210008
DF210009
DW210009
DW210010
DEPARTMENT
FORCE.
VerDate Sep<11>2014
OF
THE
18:12 Apr 20, 2021
Jkt 253001
PO 00000
Frm 00095
Fmt 4703
Special Assistant (3) ......................
Sfmt 4703
E:\FR\FM\21APN1.SGM
21APN1
Effective date
]]>Agencies
[Federal Register Volume 86, Number 75 (Wednesday, April 21, 2021)]
[Notices]
[Pages 20745-20746]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-08172]
-----------------------------------------------------------------------
NUCLEAR REGULATORY COMMISSION
Advisory Committee on the Medical Uses of Isotopes: Meeting
Notice
AGENCY: U.S. Nuclear Regulatory Commission.
ACTION: Notice of Meeting.
-----------------------------------------------------------------------
SUMMARY: The U.S. Nuclear Regulatory Commission (NRC) will convene a
public teleconference meeting of the Advisory Committee on the Medical
Uses of Isotopes (ACMUI) on May 27, 2021, to discuss the NRC staff's
assessment of medical related events for fiscal year 2020 and the ACMUI
Abnormal Occurrence Subcommittee's draft report on the proposed limited
revisions to abnormal occurrence criteria for medical events. The
meeting agenda is subject to change. Meeting information, including a
copy of the agenda and related documents, will be available on the
ACMUI's Meetings and Related Documents web page at https://www.nrc.gov/reading-rm/doc-collections/acmui/meetings/2021.html. The agenda and
related meeting documents may also be obtained by contacting Ms. Kellee
Jamerson using the information below.
DATES: The teleconference meeting will be held on Thursday, May 27,
2021, 1:00 p.m. to 5:00 p.m. Eastern Daylight Time.
------------------------------------------------------------------------
Date Webinar information
------------------------------------------------------------------------
May 27, 2021.......................... Link: https://usnrc.webex.com
Event number: 199 574 5068.
------------------------------------------------------------------------
Public Participation: The meeting will be held as a webinar using
Cisco WebEx. Any member of the public who wishes to participate in any
portion of this meeting should register in advance of the meeting by
accessing the provided link above. Upon successful registration, a
confirmation email will be generated providing the telephone bridge
line and a link to join the webinar on the day of the meeting. Members
of the public should also monitor the NRC's Public Meeting Schedule at
https://www.nrc.gov/pmns/mtg for any meeting updates. If there are any
questions regarding the meeting, persons should contact Ms. Jamerson
using the information below.
Contact Information: Kellee Jamerson, email:
[email protected], telephone: 301-415-7408.
Conduct of the Meeting
The ACMUI Chair, Darlene F. Metter, M.D., will preside over the
meeting. Dr. Metter will conduct the meeting in a manner that will
facilitate the orderly conduct of business. The following procedures
apply to public participation in the meeting:
1. Persons who wish to provide a written statement should submit an
electronic copy to Ms. Jamerson at the contact information listed
above. All written statements must be received by May 24, 2021, three
business days prior to the meeting, and must pertain to the topics on
the agenda for the meeting.
2. Questions and comments from members of the public will be
permitted during the meeting, at the discretion of the ACMUI Chairman.
3. The draft transcript and meeting summary will be available on
ACMUI's website https://www.nrc.gov/reading-rm/doc-collections/acmui/meetings/2021.html on or about July 9, 2021.
4. Persons who require special services, such as those for the
hearing impaired, should notify Ms. Jamerson of their planned
participation.
This meeting will be held in accordance with the Atomic Energy Act
of 1954, as amended (primarily Section 161a); the Federal Advisory
Committee Act (5 U.S.C. App); and the Commission's regulations in 10
CFR part 7.
[[Page 20746]]
Dated at Rockville, Maryland, this 15th day of April 2021.
For the U.S. Nuclear Regulatory Commission.
Russell E. Chazell,
Federal Advisory Committee Management Officer.
[FR Doc. 2021-08172 Filed 4-20-21; 8:45 am]
BILLING CODE 7590-01-P
